NASDAQ:COLLCollegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, COLL shares have increased by 12.0% and is now trading at $19.68. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Collegium Pharmaceutical.

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Collegium Pharmaceutical.

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.66 by $0.65. The specialty pharmaceutical company had revenue of $76.51 million for the quarter, compared to analysts' expectations of $76.64 million. Collegium Pharmaceutical had a negative net margin of 4.21% and a negative return on equity of 12.62%. The firm's revenue was up 2.7% on a year-over-year basis. During the same period last year, the company posted ($0.29) EPS. View Collegium Pharmaceutical's earnings history.

Collegium Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $300-320 million, compared to the consensus revenue estimate of $318.44 million.

8 equities research analysts have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $43.00. On average, they expect Collegium Pharmaceutical's share price to reach $32.50 in the next twelve months. This suggests a possible upside of 65.1% from the stock's current price. View analysts' price targets for Collegium Pharmaceutical.

News stories about COLL stock have been trending very negative on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCollegium Pharmaceutical.

Some companies that are related to Collegium Pharmaceutical include Uniqure (QURE), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Insmed (INSM), Apellis Pharmaceuticals (APLS), Ra Pharmaceuticals (RARX), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Pacira Biosciences (PCRX), TG Therapeutics (TGTX) and Ligand Pharmaceuticals (LGND). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Canopy Growth (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD) and GW Pharmaceuticals PLC- (GWPH).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (14.86%), BlackRock Inc. (7.28%), Camber Capital Management LP (5.82%), Franklin Resources Inc. (5.33%), Perceptive Advisors LLC (4.52%) and Rock Springs Capital Management LP (3.42%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View institutional ownership trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Rock Springs Capital Management LP, Mackay Shields LLC, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Squarepoint Ops LLC, Alliancebernstein L.P., and UBS Group AG. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, and Scott Dreyer. View insider buying and selling activity for Collegium Pharmaceutical.

COLL stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Perceptive Advisors LLC, Invesco Ltd., Janus Henderson Group PLC, Vivo Capital LLC, Mesirow Financial Investment Management Equity Management, Acadian Asset Management LLC, and Two Sigma Investments LP. View insider buying and selling activity for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $19.68.

Collegium Pharmaceutical has a market capitalization of $675.81 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.